Quantitative Analysis of Myocardial Uptake of 99mTclabeled Bone Radiopharmaceuticals Using New Whole-body CZT-based SPECT-CT Cameras, at Baseline and During Medical Treatment With Tafamidis in Patients With Cardiac Transthyretin Amyloidosis
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Pharmacodynamics
- Acronyms REMOD-TTR
Most Recent Events
- 31 Jan 2025 Planned End Date changed from 15 Mar 2023 to 15 Jun 2025.
- 31 Jan 2025 Planned primary completion date changed from 15 Sep 2022 to 15 Jun 2025.
- 08 Mar 2022 Planned End Date changed from 15 Mar 2022 to 15 Mar 2023.